Skip to content

Study · Observational study · 2025

9 results

Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.

Popoviciu MS, Reurean-Pintilei D, Salmen T, Rus M, Ferician A, Sava C, Ardelean AI, Moroianu LA, Pantea Stoian A

Biomedicines5 Sept 2025

PMID41007739 (opens in a new tab)PMCIDPMC12467173 (opens in a new tab)DOI10.3390/biomedicines13092174 (opens in a new tab)PepBankPUB-41007739
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

Background/Objectives: Obesity and type 2 diabetes mellitus (T2DM) have a continuously increasing prevalence and often co-exist, exacerbating cardiometabolic risk. GLP-1 receptor agonists (GLP-1 RAs) are recommended as first-line therapy for patients with T2DM and excess weight, particularly when cardiovascular risk is present. This study assessed the real-world effectiveness of available GLP-1 RAs in Romania on glycemic control, body weight reduction (BWR), and waist circumference (WC) in T2DM patients with excess weight. Methods: A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2). Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months. Parameters assessed included HbA1c, body weight, BMI, and WC. Results: All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05). Dulaglutide had the most significant impact on HbA1c (-6.69 ± 0.91%), while injectable semaglutide led to the most notable BWR (-4.60 ± 2.74 kg) and WC reduction, especially among male patients. No significant differences in treatment effect were observed concerning the patient's age, gender, or T2DM duration. Conclusions: In real-world clinical practice, GLP-1 RAs provide significant metabolic benefits and should be considered as part of individualized treatment strategies for T2DM patients who are overweight or obese.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, dulaglutide use was linked to lower HbA1c.

    In plain wordsIn Romanian adults with diabetes and excess weight, dulaglutide use was linked to lower long-term blood sugar.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −6.69%
    dulaglutide

    Source sentences

    Summary
    Dulaglutide had the most significant impact on HbA1c (-6.69 ± 0.91%),
    3 context sentences
    Summary · context
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  2. 02HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, dulaglutide use was linked to lower BMI.

    In plain wordsIn Romanian adults with diabetes and excess weight, dulaglutide use was linked to lower BMI.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  3. 03HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, dulaglutide use was linked to lower waist circumference.

    In plain wordsIn Romanian adults with diabetes and excess weight, dulaglutide use was linked to a smaller waist.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  4. 04HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, oral or injectable semaglutide use was linked to lower HbA1c.

    In plain wordsIn Romanian adults with diabetes and excess weight, semaglutide use was linked to lower long-term blood sugar.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  5. 05HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, oral or injectable semaglutide use was linked to lower BMI.

    In plain wordsIn Romanian adults with diabetes and excess weight, semaglutide use was linked to lower BMI.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  6. 06HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, semaglutide use was linked to lower waist circumference, most notably with injections, especially in males.

    In plain wordsIn Romanian adults with diabetes and excess weight, semaglutide use was linked to a smaller waist, especially with injections in males.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide had the most significant impact on HbA1c (-6.69 ± 0.91%), while injectable semaglutide led to the most notable BWR (-4.60 ± 2.74 kg) and WC reduction, especially among male patients.
    3 context sentences
    Summary · context
    All treatments significantly improved the patients' HbA1c, BMI, and WC (p < 0.05).
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.
  7. 07HumanObservational studyEfficacy outcome

    In Romanian adults with diabetes and excess weight, injectable semaglutide use was linked to a body weight reduction of 4.60 kg.

    In plain wordsIn Romanian adults with diabetes and excess weight, injectable semaglutide use was linked to lower body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseInjectable semaglutide body weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −4.6 kg
    injectable semaglutide

    Source sentences

    Summary
    Dulaglutide had the most significant impact on HbA1c (-6.69 ± 0.91%), while injectable semaglutide led to the most notable BWR (-4.60 ± 2.74 kg) and WC reduction, especially among male patients.
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In Romanian adults with diabetes, pooled GLP-1 treatments showed no significant treatment-effect differences by age, gender, or diabetes duration.

    In plain wordsIn Romanian adults with diabetes, pooled GLP-1 treatment effects did not differ significantly by age, gender, or diabetes duration.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeTreatment effect by age, gender, and diabetes duration
    Study

    n = 311

    Outcome group
    Overall treatment effect · Metabolic and weight

    Source sentences

    Summary
    No significant differences in treatment effect were observed concerning the patient's age, gender, or T2DM duration.
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In Romanian adults with diabetes, pooled GLP-1 treatments showed no significant treatment-effect differences by age, gender, or diabetes duration.

    In plain wordsIn Romanian adults with diabetes, pooled GLP-1 treatment effects did not differ significantly by age, gender, or diabetes duration.

    Peptide
    Semaglutide
    Outcome
    No significant changeTreatment effect by age, gender, and diabetes duration
    Study

    n = 311

    Outcome group
    Overall treatment effect · Metabolic and weight

    Source sentences

    Summary
    No significant differences in treatment effect were observed concerning the patient's age, gender, or T2DM duration.
    2 context sentences
    Summary · context
    A prospective observational study was conducted on 311 adults with T2DM (glycated hemoglobin (HbA1c) > 7.2%, body mass index (BMI) ≥ 25 kg/m2).
    Summary · context
    Patients received exenatide, semaglutide (either oral or injectable), or dulaglutide and were monitored for a period of 6 months.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.